Terpenes & terpenoids as platform molecules

01Overview and value chain

Markers: [EC: REACH & food-flavoring regulation (EU 1334/2008) | OECD: Industrial biotechnology | Regulator: FDA (US), EFSA (EU), REACH (EU)]

Terpenes and terpenoids — isoprenoid molecules built from five-carbon isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) units — are shifting from plant extraction and petrochemical synthesis to precision fermentation as a platform-chemical category spanning cosmetics, flavors and fragrances, pharmaceuticals and fuel additives. Amyris pioneered the shift at scale: its Biofene fermentation platform produces trans-beta-farnesene from sugarcane-derived sucrose in engineered Saccharomyces cerevisiae, which is then hydrogenated and dimerized into Neossance Squalane — a 100% USDA-certified biobased, Ecocert-approved cosmetic emollient that has captured an estimated 40% of the global high-purity squalane market as of late 2025, produced across four independent fermentation lines at its Barra Bonita facility in Brazil. Manus Bio holds patented enzyme technology (engineered cytochrome P450 and SrKO oxidase variants) for converting sesquiterpenes such as valencene into oxygenated derivatives like nootkatone. In Europe, Evolva and Isobionics (acquired by BASF) both commercialize fermentation-derived valencene at food-grade purity — Isobionics under its Valencene Pure brand, with regulatory acceptance in Japan since 2020, and Evolva at up to 94% purity meeting EU flavor-ingredient rules — while Givaudan continues to launch new fragrance-precursor molecules (Scentaurus PolyDoux, February 2026) alongside its long-standing terpene-derived ingredient lines. China remains, by comparison, primarily an exporter of naturally extracted terpene feedstocks (citrus-processing d-limonene, turpentine derivatives) rather than a confirmed precision-fermentation terpene platform at US/EU scale.

The key directions of terpenes and terpenoids as platform molecules are:

1. Mevalonate (MVA) pathway engineering: re-engineering yeast’s native isoprenoid pathway — most notably a truncated, membrane-anchor-free HMG-CoA reductase (tHMGR) plus extra copies of the acetyl-CoA and FPP-synthase genes — to maximize flux toward a target terpene.
2. Terpene synthase and oxidase engineering: installing the specific synthase (limonene synthase, farnesene synthase) or oxidase (SrKO-class valencene oxidase) that converts a universal prenyl-pyrophosphate precursor into the target monoterpene, sesquiterpene or oxygenated derivative.
3. In-situ product sequestration (ISPS): continuously extracting the terpene into a biocompatible organic phase during fermentation, since terpenes are membrane-toxic to the host cell above roughly 1-2 g/L in the aqueous phase.
4. Catalytic downstream conversion: hydrogenating or dimerizing a fermented terpene precursor (e.g., farnesene to squalane) to reach the final commercial molecule.

Sectoral value chain

[Sugar / lipid feedstock] ──> [Fermentation (MVA/MEP pathway)] ──> [In-situ extraction & separation] ──> [Catalytic refinement]
                                                                                                                  │
                                                                                                    (Distillation / hydrogenation)
                                                                                                                  │
                                                                                                                  ▼
[B2B release: cosmetics, F&F, fuel] <─── [QA/QC & compliance (REACH, ASTM D6866)] <─── [Purification]

Value chain levels

Cross-cutting technologies of the sector:

• Truncated HMG-CoA reductase (tHMGR) pathway engineering: removing the membrane-anchor domain of the rate-limiting mevalonate-pathway enzyme so it stays soluble and active at high copy number, the standard yeast engineering move behind Amyris’s Biofene platform.
• Terpene synthase / oxidase engineering: installing a specific synthase (limonene synthase converting GPP to limonene) or an engineered P450/SrKO-class oxidase (converting valencene to nootkatone) to reach the exact target molecule.
• In-situ product sequestration: an organic solvent overlay added during fermentation that continuously removes the terpene from the toxic aqueous phase, the standard fix for terpenes’ membrane toxicity above roughly 1-2 g/L.

02US

The United States hosts the platform’s most scaled commercial producer (Amyris) alongside enzyme-engineering specialists building the next generation of oxygenated terpenoids.

Amyris’s squalane-scale fermentation, Manus Bio’s oxidase-engineered nootkatone, post-2024 B2B pivot

• Amyris: its Biofene fermentation platform converts Brazilian sugarcane sucrose into trans-beta-farnesene via engineered S. cerevisiae, then hydrogenates and dimerizes it into Neossance Squalane, holding an estimated 40% share of the global high-purity squalane market as of late 2025 across four fermentation lines at its Barra Bonita, Brazil facility; the company restructured out of Chapter 11 in 2024 to focus on B2B ingredient supply for partners including Givaudan and DSM-Firmenich.
• Manus Bio: holds patented technology (filed and granted 2024-2026) for producing oxygenated sesquiterpenes such as nootkatone and nootkatol from valencene using engineered cytochrome P450 and SrKO-class oxidase enzymes expressed in bacterial or yeast host cells.
• Regulatory context: the FDA’s GRAS (Generally Recognized as Safe) pathway for fermentation-derived flavor and fragrance molecules continues to be the standard route to market for US-produced terpenes in food, cosmetic and fragrance applications.

03CN

China’s terpene sector remains centered on natural extraction and export of feedstocks rather than a confirmed, at-scale precision-fermentation platform comparable to its US/EU peers.

Natural feedstock export base, REACH-oriented compliance for exporters, no independently confirmed fermentation-scale producer

• Natural feedstock base: China remains a major global source of naturally extracted terpene feedstocks — citrus-processing byproduct d-limonene and pine-derived turpentine fractions — supplying downstream fragrance, solvent and specialty-chemical formulators.
• Export compliance orientation: Chinese exporters of terpene-derived chemicals into the EU market operate under REACH registration and increasingly pursue ISCC PLUS-style sustainability certification to meet buyer requirements.
• Fermentation-platform gap: unlike the US and EU, no China-based precision-fermentation terpene producer could be independently confirmed via a live 2026 source at the scale of Amyris, Evolva or Isobionics — the sector’s build-out here lags its natural-extraction base.

04EU

Europe hosts two independent commercial valencene-fermentation producers plus a leading fragrance house continuing to launch new terpene-adjacent ingredients.

Isobionics/BASF and Evolva’s food-grade valencene, Givaudan’s 2026 fragrance-precursor launches, EU flavor-regulation compliance

• Isobionics (BASF): commercializes fermentation-derived valencene under its Valencene Pure brand at food-grade purity, with regulatory acceptance in Japan since 2020 and continued production scale-up under BASF ownership.
• Evolva: produces fermentation-derived valencene at up to 94% purity, meeting EU flavor-ingredient regulation (EU 1334/2008) requirements for use in food and beverage applications.
• Givaudan: launched Scentaurus PolyDoux, the latest addition to its fragrance-precursor palette, in February 2026, and continued to unveil new Active Beauty ingredient innovations at in-cosmetics Global 2026 — part of a long-standing terpene-derived ingredient portfolio (patchoulol, ambroxide-class molecules) alongside partners such as Amyris.

05Leading companies and research institutes

06Tech stack and innovations

The terpene-platform stack pairs isoprenoid pathway engineering with downstream extraction and catalytic conversion to reach a specific commercial molecule:

1. Mevalonate pathway engineering (tHMGR):
   • Truncating HMG-CoA reductase to remove its membrane-anchor domain keeps the rate-limiting mevalonate-pathway enzyme soluble and stable at high expression levels, the core engineering move behind scaled yeast-based terpene platforms such as Amyris’s Biofene.
2. Terpene synthase and oxidase engineering:
   • Installing a specific terminal enzyme — a synthase converting a universal prenyl-pyrophosphate precursor into a target terpene, or an oxidase (SrKO-class, as used by Manus Bio) converting one terpene into an oxygenated derivative like nootkatone — determines which exact molecule a given engineered strain produces.
3. In-situ product sequestration (ISPS):
   • Because terpenes are toxic to the host cell’s membrane above roughly 1-2 g/L in the aqueous phase, an organic solvent phase is fed continuously into the fermenter to extract the terpene as it is produced, allowing much higher overall titers than would otherwise be possible.

07Value chains and production pipelines

Industrial pipeline for fermentation-derived squalane from trans-beta-farnesene

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Aerobic fed-batch       │ ───> │ 2. In-situ farnesene       │
│    yeast fermentation       │      │    extraction (ISPS)       │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Vacuum distillation to  │ <─── │ 3. Phase separation &      │
│    high-purity farnesene   │      │    crude oil recovery      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Catalytic hydrogenation │ ───> │ 6. Filtration, QA/QC &     │
│    to squalane                │      │    B2B release               │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Aerobic fed-batch yeast fermentation

Engineered S. cerevisiae carrying a truncated HMG-CoA reductase and an overexpressed farnesene synthase is grown in fed-batch mode on sugarcane-derived sucrose, secreting trans-beta-farnesene as fermentation proceeds.

Stage 2: In-situ farnesene extraction (ISPS)

A biocompatible organic solvent phase is continuously introduced into the fermenter, partitioning the secreted farnesene out of the toxic aqueous phase and protecting the yeast from membrane damage as titers rise.

Stage 3: Phase separation and crude oil recovery

The fermentation broth is processed through centrifugal separators that split it into a yeast-biomass fraction, an aqueous fraction and the crude farnesene oil phase, which is then washed to remove residual cell-culture solids.

Stage 4: Vacuum distillation to high-purity farnesene

The crude oil undergoes vacuum distillation to strip residual fatty acids and yeast metabolites, yielding trans-beta-farnesene at the high purity required for downstream catalytic conversion.

Stage 5: Catalytic hydrogenation to squalane

The purified farnesene is hydrogenated and dimerized over a metal catalyst under pressurized hydrogen, saturating its double bonds to yield stable, fully saturated squalane (C30H62).

Stage 6: Filtration, QA/QC and B2B release

The product is filtered to remove residual catalyst, analyzed by GC-MS to confirm purity and biogenic carbon content, and packaged for shipment to cosmetic and pharmaceutical formulators under long-term B2B supply agreements.